Control of cancer-related pain with MS contin®: A comparison between 12-hourly and 8-hourly administration
- 31 August 1995
- journal article
- clinical trial
- Published by Elsevier in Journal of Pain and Symptom Management
- Vol. 10 (6) , 416-422
- https://doi.org/10.1016/0885-3924(95)00063-5
Abstract
No abstract availableKeywords
This publication has 7 references indexed in Scilit:
- Integration of pain management into comprehensive cancer careCancer, 1989
- Pharmacokinetics and clinical efficacy of oral morphine solution and controlled-release morphine tablets in cancer patientsCancer, 1989
- Oral controlled-release morphine sulfate. Analgesic efficacy and side effects of a 100-mg tablet in cancer pain patientsCancer, 1989
- Controlled-release morphine (MST contin) in advanced cancer. The European experienceCancer, 1989
- Analgesic response to single and multiple doses of controlled-release morphine tablets and morphine oral solution in cancer patientsCancer, 1989
- The United States experience with oral controlled-release morphine (MS contin tablets).parts i and ii. review of nine dose titration studies and clinical pharmacology of 15-mg, 30-mg, 60-mg, and 100-mg tablet strengths in normal subjectsCancer, 1989
- The Treatment of Cancer PainNew England Journal of Medicine, 1985